Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?

Best Practice and Research: Clinical Haematology

Volumn 25, Issue 4, 2012, Pages 443-451

  Steensma, David P ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

azacitidine; decitabine; hypomethylating agent; myelodysplastic syndrome (MDS)

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; [4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; ARSENIC TRIOXIDE; AZACITIDINE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; ENTINOSTAT; ETANERCEPT; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LENALIDOMIDE; PANOBINOSTAT; ROMIDEPSIN; ROMIPLOSTIM; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; CHROMOSOME 5Q; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; DNA DAMAGE; DNA METHYLATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INDUCTION CHEMOTHERAPY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MONOTHERAPY; MOUTH ULCER; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SOMATIC MUTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84870664723     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2012.10.007     Document Type: Review

References (65)

1. G.M. Keating Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia Drugs 72 2012 1111 1136
2. G. Garcia-Manero, and P. Fenaux Hypomethylating agents and other novel strategies in myelodysplastic syndromes J Clin Oncol 29 2011 516 523
3. M.A. Sekeres, W.M. Schoonen, and H. Kantarjian Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys J Natl Cancer Inst 100 2008 1542 1551
4. L.R. Silverman Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents Leuk Res 33 Suppl. 2 2009 S18 S21
5. E. Jabbour, G. Garcia-Manero, and N. Batty Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy Cancer 116 2010 3830 3834
6. T. Prebet, S.D. Gore, and B. Esterni Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure J Clin Oncol 29 2011 3322 3327
7. T.M. Kadia, E. Jabbour, and H. Kantarjian Failure of hypomethylating agent-based therapy in myelodysplastic syndromes Semin Oncol 38 2011 682 692
8. National Center for Health Statistics. Health, United States, 2008, with Chartbook. Available at: http://www.cdc.gov/nchs/data/hus/hus08.pdf [accessed 07.06.12].
9. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 2009 223 232
10. R. Itzykson, and P. Fenaux Optimizing hypomethylating agents in myelodysplastic syndromes Curr Opin Hematol 19 2012 65 70
11. M.C. Ornstein, and M.A. Sekeres Combination strategies in myelodysplastic syndromes Int J Hematol 95 2012 26 33
12. D.P. Steensma, and R.M. Stone Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes Hematol Oncol Clin North Am 24 2010 389 406
13. S.D. Gore, and E.R. Hermes-DeSantis Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes Cancer Control 16 Suppl. 2-10 2009
14. M.J. Walter, D. Shen, and L. Ding Clonal architecture of secondary acute myeloid leukemia N Engl J Med 366 2012 1090 1098
15. H. Kantarjian, J.P. Issa, and C.S. Rosenfeld Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 2006 1794 1803
16. M. Lubbert, S. Suciu, and L. Baila Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group J Clin Oncol 29 2011 1987 1996
17. L.R. Silverman, E.P. Demakos, and B.L. Peterson Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia group B J Clin Oncol 20 2002 2429 2440
18. A.B. Kornblith, J.E. Herndon, and L.R. Silverman Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study J Clin Oncol 20 2002 2441 2452
19. P. Wijermans, M. Lubbert, and G. Verhoef Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients J Clin Oncol 18 2000 956 962
20. D.P. Steensma Decitabine treatment of patients with higher-risk myelodysplastic syndromes Leuk Res 33 Suppl. 2 2009 S12 S17
21. L.R. Silverman, D.R. McKenzie, and B.L. Peterson Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B J Clin Oncol 24 2006 3895 3903
22. M. Ozbalak, M. Cetiner, and H. Bekoz Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience Hematol Oncol 30 2012 76 81
23. V. Santini, P. Fenaux, and G.J. Mufti Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine Eur J Haematol 85 2010 130 138
24. R. Itzykson, S. Thepot, and B. Quesnel Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine Blood 117 2011 403 411
25. D.Y. Kim, J.H. Lee, and J.H. Lee Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine Ann Hematol 2009
26. R. Itzykson, S. Thepot, and V. Eclache Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine Leukemia 25 2011 1207 1209
27. B. Ruter, P. Wijermans, and R. Claus Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7 Blood 110 2007 1080 1082
28. H. Kantarjian, Y. Oki, and G. Garcia-Manero Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 2007 52 57
29. D.P. Steensma, M.R. Baer, and J.L. Slack Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial J Clin Oncol 27 2009 3842 3848
30. L.H. van der Helm, C. Alhan, and P.W. Wijermans Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme Br J Haematol 155 2011 599 606
31. E.E. Cameron, K.E. Bachman, and S. Myohanen Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 21 1999 103 107
32. S.S. Palii, B.O. Van Emburgh, and U.T. Sankpal DNA methylation inhibitor 5-aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B Mol Cell Biol 28 2008 752 771
33. T.E. Fandy, J.G. Herman, and P. Kerns Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies Blood 114 2009 2764 2773
34. S.D. Gore In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? Leuk Res 33 Suppl. 2 2009 S2 S6
35. J.P. Issa, G. Garcia-Manero, and F.J. Giles Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 2004 1635 1640
36. L. Shen, H. Kantarjian, and Y. Guo DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes J Clin Oncol 28 2010 605 613
37. T. Qin, R. Castoro, and S. El Ahdab Mechanisms of resistance to decitabine in the myelodysplastic syndrome PLoS ONE 6 2011 e23372
38. R. Bejar, K. Stevenson, and O. Abdel-Wahab Clinical effect of point mutations in myelodysplastic syndromes N Engl J Med 364 2011 2496 2506
39. R. Bejar, R. Levine, and B.L. Ebert Unraveling the molecular pathophysiology of myelodysplastic syndromes J Clin Oncol 29 2011 504 515
40. M. Ko, Y. Huang, and A.M. Jankowska Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 Nature 468 2010 839 843
41. M.A. McDevitt Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies Semin Oncol 39 2012 109 122
42. R. Itzykson, O. Kosmider, and T. Cluzeau Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias Leukemia 25 2011 1147 1152
43. F. Traina Impact of molecular mutations on treatment response to hypomethylating agents in MDS Blood 118 2011 abstr 461
44. M.A. Sekeres, R.S. Komrokji, and J.E. Lancet Final results from the phase 2 continuation study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes (MDS) Blood 118 2011 abstr 607
45. Y. Sugimoto, M.A. Sekeres, and H. Makishima Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide J Hematol Oncol 5 4 2012
46. T. Braun, R. Itzykson, and A. Renneville Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial Blood 118 2011 3824 3831
47. D.P. Steensma Novel therapies for myelodysplastic syndromes Hematol Oncol Clin North Am 24 2010 423 441
48. L.R. Silverman, A. Verma, and R. Odchimar-Reissig A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the New York Cancer Consortium Blood 112 2008 1252 abstr 3656
49. T. Prebet, S. Gore, and Z. Sun Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US leukemia intergroup trial E1905 Blood 116 2010 abstr 601
50. P.G. Smith, T. Traore, and S. Grossman Azacitidine/decitabine synergism with the NEDD8-activating enzyme inhibitor MLN4924 in pre-clinical AML models Blood 118 2010 abstr 578
51. B.L. Scott, A. Ramakrishnan, and B. Storer Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept Br J Haematol 148 2010 944 947
52. J.S. Welch, J.M. Klco, and F. Gao Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study Am J Hematol 86 2011 796 800
53. P.L. Greenberg, G. Garcia-Manero, and M.R. Moore Efficacy and safety of romiplostim in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine Blood 114 2009 abstr 1769
54. H.M. Kantarjian, F.J. Giles, and P.L. Greenberg Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy Blood 116 2010 3163 3170
55. D.P. Steensma Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes Biol Blood Marrow Transplant 2012
56. D.Y. Kim, J.H. Lee, and Y.H. Park Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome Bone Marrow Transplant 47 2012 374 379
57. P.L. Greenberg, E. Attar, and J.M. Bennett NCCN clinical practice guidelines in Oncology: myelodysplastic syndromes J Natl Compr Canc Netw 9 2011 30 56
58. A.T. Gerds, T.A. Gooley, and E.H. Estey Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS Biol Blood Marrow Transplant 2012
59. M. de Lima, S. Giralt, and P.F. Thall Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study Cancer 116 2010 5420 5431
60. E. Jabbour, S. Giralt, and H. Kantarjian Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia Cancer 115 2009 1899 1905
61. J. Bolanos-Meade, B.D. Smith, and S.D. Gore 5-Azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation Biol Blood Marrow Transplant 17 2011 754 758
62. U. Platzbecker, M. Wermke, and J. Radke Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial Leukemia 26 2012 381 389
63. N. Engel, and A. Rank Epigenomics in hematopoietic transplantation: novel treatment strategies Epigenomics 3 2011 611 623
64. G. Lal, N. Zhang, and W. van der Touw Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation J Immunol 182 2009 259 273
65. O.C. Goodyear, M. Dennis, and N.Y. Jilani Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) Blood 119 2012 3361 3369